These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36465748)

  • 1. Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report.
    Khan S; Mustafa A; Elhosseiny SM; Rizvi T; Lafferty J
    Cureus; 2022 Oct; 14(10):e30923. PubMed ID: 36465748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete heart block associated with Remdesivir in COVID-19: a case report.
    Selvaraj V; Bavishi C; Patel S; Dapaah-Afriyie K
    Eur Heart J Case Rep; 2021 Jul; 5(7):ytab200. PubMed ID: 34222786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation.
    Edwards SJ; Karner C; Trevor N; Wakefield V; Salih F
    Health Technol Assess; 2015 Aug; 19(65):1-210. PubMed ID: 26293406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.
    Barkas F; Styla CP; Bechlioulis A; Milionis H; Liberopoulos E
    J Cardiovasc Dev Dis; 2021 Feb; 8(2):. PubMed ID: 33673216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
    Maheshwari M; Athiraman H
    Cureus; 2021 Nov; 13(11):e19919. PubMed ID: 34956798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.
    Devgun JM; Zhang R; Brent J; Wax P; Burkhart K; Meyn A; Campleman S; Abston S; Aldy K;
    JAMA Netw Open; 2023 Feb; 6(2):e2255815. PubMed ID: 36787141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.
    Hajimoradi M; Sharif Kashani B; Dastan F; Aghdasi S; Abedini A; Naghashzadeh F; Mohamadifar A; Keshmiri MS; Noorali S; Lookzadeh S; Alizadeh N; Siri MA; Tavasolpanahi M; Abdolmohammadi Y; Shafaghi M; Rouhani ZS; Shafaghi S
    Front Pharmacol; 2022; 13():1107198. PubMed ID: 36733376
    [No Abstract]   [Full Text] [Related]  

  • 8. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study.
    Alsowaida YS; Shehadeh F; Kalligeros M; Mylonakis E
    Front Pharmacol; 2023; 14():1106044. PubMed ID: 36817161
    [No Abstract]   [Full Text] [Related]  

  • 10. Remdesivir-Induced Extreme Sinus Bradycardia in COVID-19.
    Wasef N; Hamilton S; Fatima T; Osgood E
    Cureus; 2022 Jul; 14(7):e27307. PubMed ID: 35910702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir-Associated Significant Bradycardia: A Report of Three Cases.
    Shirvani M; Sayad B; Shojaei L; Amini A; Shahbazi F
    J Tehran Heart Cent; 2021 Apr; 16(2):79-83. PubMed ID: 35082876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab-Associated Myocarditis Initially Presenting With Sinus Bradycardia Progressing Into Complete Heart Block.
    Bae S; Vaysblat M; Ng J; Beccarino N; Makaryus J; Sarkar K
    Cureus; 2023 Jun; 15(6):e40171. PubMed ID: 37431327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syncope triggered by atrial flutter in a patient with a pacemaker: cross-stimulation-a case report.
    Durán-Bobin O; Crespo-Mancebo F; Elices-Teja J; González-Juanatey C
    Eur Heart J Case Rep; 2021 Feb; 5(2):ytab041. PubMed ID: 33629026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyme Carditis: A Rare Presentation of Sinus Bradycardia Without Any Conduction Defects.
    Grella BA; Patel M; Tadepalli S; Bader CW; Kronhaus K
    Cureus; 2019 Sep; 11(9):e5554. PubMed ID: 31695976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate.
    Chen YZ; Lin MS; Lin YP; Liu YZ; Yang CJ
    J Microbiol Immunol Infect; 2023 Oct; 56(5):970-976. PubMed ID: 37407291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports.
    Abdelmajid A; Osman W; Musa H; Elhiday H; Munir W; Al Maslamani MA; Elmekaty EZ
    IDCases; 2021; 26():e01254. PubMed ID: 34401329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual chamber cardiac pacing in children: Single chamber pacing dual chamber sensing cardiac pacemaker or dual chamber pacing and sensing cardiac pacemaker?
    Bostan OM; Celiker A; Karagöz T; Ozer S; Ozme S
    Pediatr Int; 2002 Dec; 44(6):635-40. PubMed ID: 12421261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial standstill: an indication for rate responsive pacing.
    Solti F; Rényi-Vámos F; Gyöngy T
    Pacing Clin Electrophysiol; 1990 Jul; 13(7):830-2. PubMed ID: 1695737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-chamber pacing using a hybrid transvenous and leadless pacing approach.
    Nona P; Altawil M; Khan E; Maskoun W
    Pacing Clin Electrophysiol; 2021 Apr; 44(4):751-754. PubMed ID: 33559285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.